What Factors Propelled The Growth Of The Irritable Bowel Syndrome (IBS) Treatment Market In The Past?
The irritable bowel syndrome (ibs) treatment market has seen considerable growth due to a variety of factors.
•In recent times, the market size for the treatment of irritable bowel syndrome (IBS) has experienced a swift expansion. The market is set to increase from $2.79 billion in 2024 to approximately $3.07 billion in 2025, registering a compound annual growth rate (CAGR) of 10.2%.
The past growth in this sector can be attributed to factors such as an upsurge in the incidence of IBS, amplified patient consciousness, stress and lifestyle considerations, patient lobbying and support associations, as well as health insurance reimbursement policies.
What Is The Projected Growth And Market Size For The Irritable Bowel Syndrome (IBS) Treatment Sector?
The irritable bowel syndrome (ibs) treatment market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipated to experience speedy expansion in upcoming years, the market size of treatment for irritable bowel syndrome (IBS) is set to rise to $4.93 billion in 2029, representing a compound annual growth rate (CAGR) of 12.5%.
This predicted growth in the forecast period is due to factors such as patient-focused healthcare models, microbial treatments, the application of blockchain in healthcare, patient-documented outcomes, quick-track regulatory programs, and the compatibility of health data. Notable trends for the forecast period encompass the incorporation of digital health interventions, advancements in the field of diagnostic technologies, amplification of research and developments investments, strategic collaborations and partnerships, as well as the emergence of non-drug therapies.
What Are The Core Factors Supporting Growth In The Irritable Bowel Syndrome (IBS) Treatment Market?
The anticipated growth of the irritable bowel syndrome treatment market is fueled by an increasing prevalence of irritable bowel syndrome (IBS), a chronic condition affecting the large intestine. The escalation in IBS cases can be attributed to unhealthy living conditions, poor dietary choices, pollution exposure, and heightened stress levels. Treatments for IBS are instrumental in minimizing the severity and regularity of IBS symptoms, enhancing life quality, and assisting individuals in better handling their conditions. For example, research and education non-profit organization based in the US, the International Foundation for Gastrointestinal Disorders (IFFGD), reports that around 5-10% of the world's population will be diagnosed with IBS in 2023, and the condition affects between 25 and 45 million individuals in the United States alone. Consequently, the increasing prevalence of irritable bowel syndrome (IBS) is catalyzing the expansion of the IBS treatment market.
What Are The Major Segments Within The Global Irritable Bowel Syndrome (IBS) Treatment Market?
The irritable bowel syndrome (IBS) treatment market covered in this report is segmented –
1) By Drug Type: Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Other Drugs
2) By Indication: IBS With Constipation, IBS With Diarrhea, IBS With Alternating Constipation And Diarrhea
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
4) By End-Users: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Lubiprostone: Chronic Idiopathic Constipation Treatment, Irritable Bowel Syndrome with Constipation (IBS-C) Treatment
2) By Linaclotide: IBS-C Treatment, Chronic Idiopathic Constipation Treatment
3) By Eluxadoline: IBS with Diarrhea (IBS-D) Treatment
4) By Rifaximin: IBS-D Treatment, Small Intestinal Bacterial Overgrowth (SIBO) Treatment
5) By Alosetron: Severe IBS-D Treatment for Women
6) By Other Drugs: Prucalopride, Tenapanor, Plecanatide
Pre-Book The Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Irritable Bowel Syndrome (IBS) Treatment Market?
The emergence of product innovations is a significant trend being observed in the Irritable Bowel Syndrome (IBS) market. Key players in the IBS market are focusing their energies on the development of new, innovative, and advanced products to consolidate their market position. As an example, in April 2022, Ardelyx, a biotechnology firm based in the US, introduced IBSRELA, an industry-leading treatment for IBS-C in adults. This is the first and sole NHE3 inhibitor available for the treatment of adult IBS-C. IBSRELA marks Ardelyx's first FDA-approved medicine and represents the first new mechanism therapy developed for IBS-C in nearly a decade. This provides a considerable new treatment alternative for symptoms such as constipation, bloating, and stomach pain that are associated with this debilitating condition.
Who Are the Key Players in the Irritable Bowel Syndrome (IBS) Treatment Market?
Major companies operating in the irritable bowel syndrome (IBS) treatment market include:
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• AbbVie Inc.
• Novartis AG
• AstraZeneca plc
• Abbott Laboratories
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Astellas Pharma Inc.
• Biogen Inc.
• Bausch Health Companies Inc.
• Ironwood Pharmaceuticals Inc.
• Sebela Pharmaceuticals Inc.
• Prometheus Laboratories Inc.
• RedHill Biopharma Ltd.
• Ardelyx Inc.
• Cosmo Technologies Ltd.
• Renexxion Ireland Ltd.
• 4D Pharma plc
• Biora Therapeutics Inc.
What Is The Most Dominant Region In The Irritable Bowel Syndrome (IBS) Treatment Market?
North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the irritable bowel syndrome (IBS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
